Stockscreener 앱 받기
13.43
5.42%
-0.77
시간 외 거래:
13.43
전일 마감가:
$14.20
열려 있는:
$14.275
하루 거래량:
1.41M
Relative Volume:
0.95
시가총액:
$1.91B
수익:
-
순이익/손실:
$-45.61M
주가수익비율:
-41.51
EPS:
-0.3235
순현금흐름:
$-45.40M
1주 성능:
-9.74%
1개월 성능:
-11.82%
6개월 성능:
+18.74%
1년 성능:
+106.62%
1일 변동 폭
$13.22
$14.47
1주일 범위
$13.22
$15.79
52주 변동 폭
$5.3801
$16.12
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
13.43 | 2.02B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN
Trevi Therapeutics, Inc. (TRVI) Analyst/Investor DaySlideshow (NASDAQ:TRVI) 2026-05-15 - Seeking Alpha
Trevi Therapeutics, Inc.Common Stock (Nasdaq:TRVI) Stock Quote - FinancialContent
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
TradingKey - TradingKey
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
TRVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - sharewise.com
Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Equities Analysts Offer Predictions for TRVI Q2 Earnings - MarketBeat
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech With 59.82% Potential Upside - DirectorsTalk Interviews
NEA stake in Trevi now 10.5% on share increase (TRVI) - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Research Analysts Set Expectations for TRVI FY2030 Earnings - MarketBeat
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 - Yahoo Finance
FMR LLC shows 6.3% stake in Trevi Therapeutics (NASDAQ: TRVI) - Stock Titan
B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating - marketscreener.com
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
MSN Money - MSN
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 - Investing.com
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 By Investing.com - Investing.com Canada
Trevi Therapeutics Q1 Earnings Call Highlights - MarketBeat
Trevi Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com UK
TRVI: Cash runway into 2030 supports multiple advancing chronic cough trials and new patent coverage - TradingView
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress By Investing.com - Investing.com South Africa
Trevi Therapeutics Q1 net loss widens as R&D costs rise - TradingView
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Q1 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan
Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan
Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BRIEF-Trevi Therapeutics Q1 Net Income USD -13.192 Million - TradingView
Pictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.53%
자본화:
|
볼륨(24시간):